Clinical Trial Update: Enteric-Coated Mycophenolate Sodium on Quality of Life in Patients With Gastrointestinal Symptoms Related to Mycophenolate Mofetil Therapy After Kidney Transplantation [Phase 4]

View source ↗

Summary

Phase 4 trial update examining whether enteric-coated mycophenolate sodium improves quality of life in kidney transplant patients with GI symptoms related to my…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Transplant

Drugs mentioned

• CELLCEPT (mycophenolate mofetil hydrochloride)
• MYFORTIC (MYCOPHENOLIC ACID)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Renal Transplant | Phase 4 | Status: COMPLETED | Results posted: 2011-03-24